Search results
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Company's Board of Directors (the "Board") carefully reviewed the revised unsolicited proposal from Future Pak, LLC ("FP") to acquire the Company for $7.25 to $7.75 per share in cash plus certain Contingent Value Rights ("CVRs") and, after having consulted with the ...
Apr 17, 2024 · Vanda Pharmaceuticals ( NASDAQ: VNDA) has rejected a buyout bid from Future Pak saying the offer significantly undervalues the company. Future Pak has submitted three proposals since February to ...
Oct 16, 2023 · Vanda Pharmaceuticals (VNDA) is a net-net opportunity with a market cap of $250mm and $387mm in net cash. The market is worried about declining sales of the company's top drug. Despite the ...
Apr 17, 2024 · WIXOM, Mich., April 17, 2024--Future Pak LLC ("Future Pak") today announced that it has submitted three proposals since February to acquire all of the outstanding shares of common stock of Vanda ...
4 days ago · Vanda Pharmaceuticals Inc. (VNDA.NASDAQ): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Vanda Pharmaceuticals Inc. | Nasdaq: VNDA ...
1 day ago · Only one analyst offered a short-term price target of $5.25 for Vanda Pharmaceuticals. This represents an increase of 5.42% from the last closing price of $4.98.
Jan 23, 2024 · WASHINGTON , Jan. 23, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to evaluate VCA-894A for the treatment of a patient with Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S), caused by cryptic ...
